Theriva Biologics, Inc. (TOVX) has disclosed a new risk, in the Debt & Financing category.
Theriva Biologics, Inc. is confronting significant financial challenges that cast doubt on its operational continuity. With recurring losses and an accumulated deficit of $314.5 million as of March 31, 2024, liquidity concerns are at the forefront. The company’s working capital of $15.6 million and a cash balance of $18.4 million are insufficient to sustain operations for the next twelve months post the issuance of their financial statements. This precarious financial position necessitates urgent pursuit of additional capital to maintain operations and advance their clinical development program.
The average TOVX stock price target is $2.00, implying 378.47% upside potential.
To learn more about Theriva Biologics, Inc.’s risk factors, click here.
